Selection criteria in liver transplantation for hepatocellular carcinoma: an ongoing evolution.
作者信息
Line Pål-Dag
机构信息
Department of Transplantation Medicine, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Postboks 4950 Nydalen, 0424 Oslo, Norway.
出版信息
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrac024.
Abstract
摘要
相似文献
1
Selection criteria in liver transplantation for hepatocellular carcinoma: an ongoing evolution.肝细胞癌肝移植的选择标准：不断演变
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrac024.
2
[Liver transplantation for hepatocellular carcinoma].[肝细胞癌的肝移植]
Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):61-9. doi: 10.1016/j.gcb.2008.11.005. Epub 2008 Dec 23.
3
Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma: What Are the Optimal Criteria?肝细胞癌患者的活体肝移植：最佳标准是什么？
Liver Transpl. 2021 Jun;27(6):930-931. doi: 10.1002/lt.26003.
4
Liver transplantation for hepatocellular carcinoma: how far can we push the envelope?
Singapore Med J. 2003 Jun;44(6):309-11.
5
Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit?扩大肝细胞癌肝移植的极限：存在极限吗？
Clin Liver Dis. 2021 Feb;25(1):19-33. doi: 10.1016/j.cld.2020.08.002. Epub 2020 Oct 17.
6
Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.从肝癌肝移植中获得最佳长期结果。
Dig Dis Sci. 2019 Apr;64(4):976-984. doi: 10.1007/s10620-019-05550-5.
7
Treatment of recurrent hepatocellular carcinoma after liver transplantation.肝移植后复发性肝细胞癌的治疗
Liver Transpl. 2011 Oct;17 Suppl 2:S162-6. doi: 10.1002/lt.22361.
8
Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation".
Ann Surg. 2021 Dec 1;274(6):e832-e833. doi: 10.1097/SLA.0000000000004511.
9
[Treatment of hepatocellular carcinoma: hepatic resection and liver transplantation].
Rev Med Chir Soc Med Nat Iasi. 2005 Oct-Dec;109(4):709-12.
10
The Milan criteria: no room on the metro for the king?
Liver Transpl. 2010 Mar;16(3):252-5. doi: 10.1002/lt.22037.
引用本文的文献
1
PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature.实体器官恶性肿瘤全谱系中PET评估的代谢肿瘤体积：文献综述
Biomedicines. 2025 Jan 7;13(1):123. doi: 10.3390/biomedicines13010123.
本文引用的文献
1
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.肝癌患者肝移植选择标准的预后作用：网络荟萃分析。
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab130.
2
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
3
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.Metroticket 2.0 模型分析肝癌肝移植术后死亡的竞争风险。
Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5.
4
A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score.一种新型的肝癌患者肝移植等待期预后指标：时间-影像学-甲胎蛋白-炎症（TRAIN）评分。
Ann Surg. 2016 Nov;264(5):787-796. doi: 10.1097/SLA.0000000000001881.
5
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.肝移植治疗肝硬化患者的小肝细胞癌
N Engl J Med. 1996 Mar 14;334(11):693-9. doi: 10.1056/NEJM199603143341104.
Zotero 插件